J Gynecol Oncol.  2018 Jan;29(1):e16. 10.3802/jgo.2018.29.e16.

Survival benefit of patients with early-stage ovarian carcinoma treated with paclitaxel chemotherapeutic regimens

Affiliations
  • 1School of Health Care Administration, Taipei Medical University, Taipei, Taiwan. chtang@tmu.edu.tw
  • 2Graduate Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan.
  • 3Taiwan Cancer Registry, Taipei, Taiwan.
  • 4Taiwan Blood Services Foundation, Taipei, Taiwan.
  • 5Department of Obstetrics and Gynecology, College of Medicine, National Taiwan University, Taipei, Taiwan. wenfangcheng@yahoo.com
  • 6School of Medicine, College of Medicine and Big Data Research Centre, Fu-Jen Catholic University, New Taipei City, Taiwan.
  • 7Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.
  • 8Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan.

Abstract


OBJECTIVE
Adjuvant chemotherapy was introduced in patients with early-stage ovarian cancer (OC). The benefit of standard chemotherapeutic regimens including taxane has not been established.
METHODS
Patients with early-stage OC from the National Health Insurance Research database of Taiwan who received platinum plus cyclophosphamide (CP) or platinum plus paclitaxel (PT) for 3-6 cycles were recruited, and the disease-free survival (DFS) and overall survival (OS) were determined.
RESULTS
A total of 1,510 early-stage OC patients, including 841 who received CP regimen and 699 who received PT regimen, were included. The 2 groups had a similar estimated probability of 5-year DFS (PT vs. CP, 79.0% vs. 77.6%; p=0.410) and OS (84.6% vs. 84.3%; p=0.691). Patients >50 years of age who received the CP regimen had a lower 5-year DFS than the patients ≤50 years of age who received the CP (p<0.001) or PT regimens (p=0.001). Additionally, patients >50 years of age who received the CP regimen had a worse 5-year OS compared with the other 3 groups (p=0.019) (p=0.179 for patients >50 years of age in the PT group; p=0.002 for patients ≤50 years of age in the CP group; and p=0.061 for patients ≤50 years of age in the PT group). Patients with the CP or PT regimen for 3-5 cycles had a similar 5-year DFS and OS compared to 6 cycles (p>0.050).
CONCLUSION
Chemotherapeutic regimens with taxane could be recommended for early-stage OC patients >50 years of age.

Keyword

Ovarian Neoplasms; Drug Therapy; Taxane; Disease-Free Survival; Survival
Full Text Links
  • JGO
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr